New form of experimental immunotherapy for men with progressive mCRPC

A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination  with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Enzalutamide and quality of life in post-chemotherapy mCRPC patients

A newly published paper in The Lancet Oncology has provided data on several of the prospectively defined secondary endpoints from the AFFIRM trial of enzalutamide vs. a placebo in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after progression on treatment with docetaxel + prednisone. … READ MORE …

Phase I/II data on ODM-201 in mCRPC; and a Phase III trial in nmCRPC

ODM-201 is a new androgen receptor  inhibitor, initially developed by a Finnish company called Orion and now being developed by Orion in partnership with the German pharmaceutical company, Bayer. … READ MORE …

Another kinase inhibitor shows only “modest” activity in men with mCRPC

A relatively small Phase II trial, carried out in France and Germany, has suggested that a new kinase inhibitor called nintedanib has only “modest” activity in the treatment of post-chemotherapy, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Sunday morning’s news from the ASCO annual meeting

We commented earlier on several of the prostate cancer presentations given this morning at the American Society for Clinical Oncology (ASCO) meeting — see here and here. However, there was another important paper presented this morning. … READ MORE …

Decision about enzalutamide in chemo-naive mCRPC

According to a joint media release, issued yesterday by Medivation and Astellas, the U.S. Food & Drug Administration (FDA) has granted a priority review for the supplementary New Drug Application (sNDA) for the use of enzalutamide in the treatment of chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Custirsen does NOT significantly extend survival in men with mCRPC

OncoGenex and Teva stated earlier today that the addition of custirsen (OGX-011) to docetaxel + prednisone did not demonstrate any significant effect on the overall survival of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,132 other followers